Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

capitalpreservation1 9 posts  |  Last Activity: Sep 20, 2013 10:34 PM Member since: Jul 23, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    0

    by capitalpreservation1 Sep 17, 2013 10:57 PM
    capitalpreservation1 capitalpreservation1 Sep 20, 2013 10:34 PM Flag

    I don't think they're out of money. I suspect they have until the end of October. I do wonder if they made an announcement (update) in hopes of a pop. They've always stated that the financing would be driven mostly by an equity raise. The dilution with the stock at these levels would be significant. Regarding the RINs, I think they generated the RINs in the front months and delivered in August...play on words? I do think this company can make this work, but I wish that they were a bit less secretive on production, issues or otherwise.

  • capitalpreservation1 by capitalpreservation1 Sep 17, 2013 10:57 PM Flag

    That's the amount of fuel made in August which generated RINs. We need an update...

  • capitalpreservation1 by capitalpreservation1 Jul 25, 2013 2:56 PM Flag

    About 50k gallons of production of cellulosic gasoline and 20k gallons of cell. diesel for June. That's a great start in my opinion and encouraging for July numbers.

  • capitalpreservation1 by capitalpreservation1 Dec 20, 2012 10:30 PM Flag

    Brean Capital initiates coverage on Synta Pharma. (NASDAQ: SNTA) with a Buy. PT $12.00 saying they expect several important catalysts for lead drug candidate, Ganetespib, during 2013.

    The firm comments, "We expect several important catalysts for SNTA's lead drug candidate, Ganetespib, during 2013 with important Phase 2 data readouts in lung and breast cancer. We forecast commercial launch of Ganetespib in 2015, with global sales in 2nd-line NSCLC alone reaching $1B by 2020. SNTA has initiated the pivotal Phase 3 portion of the GALAXY program for 2nd-line NSCLC, and we expect the trial to fully enroll by YE13, with an interim analysis during 1H14 and final results by 2H14. In the meantime, we expect the company to announce final PFS data for Ganetespib from the ongoing Phase 2b portion of the GALAXY program during 1H13, with overall survival from the trial maturing in 2H13."

  • capitalpreservation1 by capitalpreservation1 Dec 20, 2012 10:29 PM Flag

    Brean Capital initiates coverage on Synta Pharma. (NASDAQ: SNTA) with a Buy. PT $12.00 saying they expect several important catalysts for lead drug candidate, Ganetespib, during 2013.

    The firm comments, "We expect several important catalysts for SNTA's lead drug candidate, Ganetespib, during 2013 with important Phase 2 data readouts in lung and breast cancer. We forecast commercial launch of Ganetespib in 2015, with global sales in 2nd-line NSCLC alone reaching $1B by 2020. SNTA has initiated the pivotal Phase 3 portion of the GALAXY program for 2nd-line NSCLC, and we expect the trial to fully enroll by YE13, with an interim analysis during 1H14 and final results by 2H14. In the meantime, we expect the company to announce final PFS data for Ganetespib from the ongoing Phase 2b portion of the GALAXY program during 1H13, with overall survival from the trial maturing in 2H13."

  • Reply to

    Brean Starts SNTA at Buy

    by predictor_98456 Dec 13, 2012 7:22 AM
    capitalpreservation1 capitalpreservation1 Dec 13, 2012 10:42 PM Flag

    Synta Pharmaceuticals Corp. (NASDAQ: SNTA) in a research note issued to investors on Thursday. The firm issued a buy rating and a $12.00 target price on the stock.
    Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Synta Pharmaceuticals Corp. from $15.00 to $22.00 in a research note to investors on Monday, October 1st. They now have a buy rating on the stock.

    Sentiment: Hold

  • Reply to

    Brean Starts SNTA at Buy

    by predictor_98456 Dec 13, 2012 7:22 AM
    capitalpreservation1 capitalpreservation1 Dec 13, 2012 10:08 PM Flag

    Brean Murray began coverage on shares of Synta Pharmaceuticals Corp. (NASDAQ: SNTA) in a research note issued to investors on Thursday. The firm issued a buy rating and a $12.00 target price on the stock.
    Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Synta Pharmaceuticals Corp. from $15.00 to $22.00 in a research note to investors on Monday, October 1st. They now have a buy rating on the stock.

  • Reply to

    10+ by Friday, 20+ by 2013

    by steett2004 Sep 17, 2012 2:47 PM
    capitalpreservation1 capitalpreservation1 Sep 17, 2012 11:28 PM Flag

    Give me a break...based on what, increased volume requirements only? Make all the stuff you want to, with these kind of margins, it's a losing game.

  • Reply to

    STWD is Dead Money

    by ferdiefor Jul 13, 2010 11:24 AM
    capitalpreservation1 capitalpreservation1 Jul 23, 2010 4:51 PM Flag

    Wait a second. How are you calculating those yields? This stock is undervalued after incorporating their latest deal(s). I see a yield of close to 9% based on today's closing price by Q4 and they will drive that yield in excess of 12-14% by mid 2011 by leveraging the portfolio. I also believe the opportunities are still coming...anyways, my 2 cents.

SNTA
0.3430.000(0.00%)Jul 22 4:00 PMEDT